ID
16625
Beschreibung
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc ( OSI Pharmaceuticals ) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Post-Treatment Assessments
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Stichworte
Versionen (3)
- 27.07.16 27.07.16 -
- 01.08.16 01.08.16 -
- 27.09.16 27.09.16 -
Hochgeladen am
27. Juli 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
TEST A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT) NCT00373425
Post-Treatment Assessment TEST A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT) NCT00373425
Beschreibung
Vital Assessment
Alias
- UMLS CUI-1
- C0031809
Beschreibung
Physical Examination
Alias
- UMLS CUI-1
- C0031809
Beschreibung
Examination Date
Datentyp
date
Alias
- UMLS CUI [1]
- C2826643
Beschreibung
Pregnancy Test
Alias
- UMLS CUI-1
- C0032976
Beschreibung
Pregnancy Test
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0032976
Beschreibung
Date of Collection
Datentyp
text
Alias
- UMLS CUI [1,1]
- C1516698
- UMLS CUI [1,2]
- C0011008
Beschreibung
Accession Number
Datentyp
text
Alias
- UMLS CUI [1]
- C2826726
Beschreibung
Biochemistry/Proteomics
Beschreibung
Reason Off Treatment
Beschreibung
Death
Alias
- UMLS CUI-1
- C0011065
Beschreibung
Death
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0011065
Beschreibung
Primary Cause of Death
Datentyp
integer
Alias
- UMLS CUI [1]
- C0007465
Beschreibung
Cause of death
Datentyp
text
Alias
- UMLS CUI [1]
- C0007465
Beschreibung
Autopsy
Datentyp
integer
Alias
- UMLS CUI [1]
- C0004398
Beschreibung
Investigator Signature
Beschreibung
Investigator Signature
Datentyp
text
Alias
- NCI Thesaurus ValueDomain
- C25704
- NCI Thesaurus Property
- C25678
- NCI Thesaurus ObjectClass
- C17089
- UMLS CUI [1]
- C2346576
Beschreibung
Investigator Signature Date
Datentyp
date
Alias
- NCI Thesaurus ObjectClass
- C19464
- NCI Thesaurus Property
- C25250
- NCI Thesaurus Property-2
- C25604
- NCI Thesaurus ValueDomain
- C25164
- NCI Thesaurus ValueDomain-2
- C25367
- UMLS CUI [1,1]
- C2346576
- UMLS CUI [1,2]
- C0011008
Ähnliche Modelle
Post-Treatment Assessment TEST A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT) NCT00373425
C0600091 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,2])
C0566251 (UMLS CUI [1,2])
C25678 (NCI Thesaurus Property)
C17089 (NCI Thesaurus ObjectClass)
C2346576 (UMLS CUI [1])
C25250 (NCI Thesaurus Property)
C25604 (NCI Thesaurus Property-2)
C25164 (NCI Thesaurus ValueDomain)
C25367 (NCI Thesaurus ValueDomain-2)
C2346576 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])